Selected HKEX Announcements | China Metallurgical Group Corporation reported new contract signings exceeding RMB 300 billion in the first five months; Youjia Innovation signed an agreement for the procurement of autonomous logistics vehicles.

① MCC reported new contract signings exceeding RMB 300 billion in the first five months—how large is its overseas business? ② Youjia Innovation signed a procurement agreement for autonomous logistics vehicles—what are the key highlights?

cls.cnJun 16 20:21

Wuxi Apptec (02359.HK) repurchased 892,600 shares on June 16 at a cost of HK$112 million.

Gelonghui, June 16 — Wuxi Apptec (02359.HK) announced that on June 16, 2026, it repurchased 892,600 shares at a total cost of HK$112 million, at a price range of HK$122.8 to HK$127.2 per share.

Gelonghui FinanceJun 16 17:21

Selected HKEX Announcements | CITIC Resources expects interim profit exceeding HK$200 million; China Coal Energy's coal sales volume declined by approximately 10% year-on-year in the first five months

① CITIC Resources expects interim profit to exceed HK$200 million—what is the year-on-year growth rate? ② China Coal Energy’s coal sales for the first five months declined by approximately 10% year-on-year—how did sales perform in May?

cls.cnJun 15 20:23

Wuxi Apptec (02359.HK) repurchased 818,000 shares at a total cost of approximately RMB 100 million.

Wuxi Apptec (02359.HK) repurchased 818,000 ordinary shares today (the 15th) on the Stock Exchange of Hong Kong at prices ranging from HK$124.1 to HK$127.8 per share, for a total consideration of approximately HK$100 million. Since the share repurchase mandate was approved on April 28, 2026, the company has cumulatively repurchased 19,256,300 shares, representing 0.6454% of its issued share capital.

AASTOCKSJun 15 17:46

Wuxi Apptec (02359.HK) repurchased 1,013,900 shares on June 15 at a cost of HK$100 million.

Gelonghui, June 15 — Wuxi Apptec (02359.HK) announced that on June 15, 2026, it repurchased 1,013,900 shares at a total cost of HK$100 million, at prices ranging from HK$97.87 to HK$99.38 per share.

Gelonghui FinanceJun 15 17:42

Billions in Share Buybacks to Stabilize Markets? As Stock Prices Remain Weak, Leading Pharmaceutical Firms Launch a 'Valuation Defense Campaign'

① Amid sustained downward pressure on share prices, several pharmaceutical companies—including Sino Biopharm, Akeso, and Wuxi Apptec—have successively announced share repurchase or management buy-in plans; ② Industry insiders believe that such repurchases can help restore market sentiment, but a meaningful re-rating of the sector will still depend on the consistent realization of commercialization and global expansion capabilities.

cls.cnJun 15 17:06